摘要
在本研究中,哮喘患者对其疾病变化的感知与临床哮喘测量值的观察变化相关,以确定患者可感知临床哮喘测量值变化的阈值。该研究纳入281名年龄在18-63岁的哮喘患者,参与白三烯拮抗剂的随机、安慰剂对照临床试验。哮喘症状评分变化相关:1)哮喘症状评分变化;2)吸入β -激动剂使用;3) 1秒用力呼气量(FEV1);4)呼气峰值流量(PEF)到一个全球性问题,该问题询问了自开始使用研究药物以来哮喘的总体变化。额外的分析检查了报告治疗(积极治疗vs安慰剂)、性别和年龄组的最低改善的差异。每项测量的患者平均最小可感知改善为:1)症状评分为-0.31分(0-6分);2) -0.81次x天(-1)用于吸入β -激动剂;3) FEV1为0.23 L; and 4) 18.79 L x min(-1) for PEF. In general placebo-treated patients and older patients, who reported minimal improvement, experienced less mean improvement from baseline than active-treated patients and younger patients, who reported minimal improvement. Determining the minimal patient perceivable improvement value for a measure may be helpful to interpret changes. However, interpretation should be carried out cautiously when reporting a single value as a clinically important change.